Animal models for mucopolysaccharidoses and their clinical relevance.
The mucopolysaccharidoses (MPS) are characterized by the accumulation of glycosaminoglycans (GAG) and result from the impaired function of one of 11 enzymes required for normal GAG degradation. MPS II was the first MPS to be defined clinically in humans and is caused by deficient activity of the enzyme iduronate-2-sulphatase. MPS VI was the first MPS recognized in an animal; since then, all but MPS IIIC and IX have been described as naturally occurring in animals or made by knock-out technology. As in humans, all are inherited as autosomal recessive traits, except for MPS II, which is X-linked. Most animal colonies have been established from single related heterozygous animals, making the affected offspring homozygous for the same mutant allele. Importantly, these models have disease pathology that is similar to that seen in humans, making the animals extremely valuable for the investigation of disease pathogenesis and the testing of therapies. Large animal homologues are similar to humans in natural genetic diversity, approaches to therapy and care, and the possibility of evaluating long-term effects of treatment. Therapeutic strategies for MPS include enzyme replacement therapy, heterologous bone marrow transplantation, and somatic cell gene transfer, all of which have been tested in animals with some success.
Haskins
M
M
Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104-6051, USA. mhaskins@vet.upenn.edu
Casal
M
M
Ellinwood
N M
NM
Melniczek
J
J
Mazrier
H
H
Giger
U
U
D000818:Animals; D002415:Cats; D002417:Cattle; D004195:Disease Models, Animal; D004285:Dogs; D020312:Dromaiidae; D006041:Goats; D006168:Guinea Pigs; D006801:Humans; D051379:Mice; D009083:Mucopolysaccharidoses / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D051381:Rats